Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 7 selected

Guidance programme

Showing 1 to 17 of 17

TitleReference numberPublishedLast updated
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891
Mosunetuzumab for treating relapsed or refractory follicular lymphomaTA892
Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcersDG52
MRI fusion biopsy systems for diagnosing prostate cancerDG53
Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuriesIPG762
Head injury: assessment and early managementNG232
Risankizumab for previously treated moderately to severely active Crohn's diseaseTA888
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Difelikefalin for treating pruritus in people having haemodialysisTA890
Diabetes (type 1 and type 2) in children and young people: diagnosis and managementNG18
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessmentHTE7
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatmentsTA881
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884

Results per page

  1. 10
  2. 25
  3. 50
  4. All